Goodies symptoms and conditions

Concerned Citizen; I just went to Singulair.com and the website is quite good. Any practitioner would know to look at the product PI which is right there and the pharmacokinetics section tells you how it works. Put your glasses on.

My doctor put me on Yasmin about 2 years ago because I had severe menstrual cramps. So bad that I had to take off of school whenever I had my period because the only way to relieve my pain was to lie in bed with a heating pad on max, and i'd still cry over how bad it was. In the beginning of taking Yasmin, I felt awesome, lighter period flow and minor cramps that actually could be relieved with midol but seeing as it was nothing compared to what I had gone through I usually didn't even take that. Now i'm 21 years old, am 15 pounds heavier, I have no energy and severe anxiety and stress. A few months ago I had this 2 week episode with a headache that wouldn't go away with advil, like a normal headache would, stomach pains, nausea and vomiting. I had never felt so awful in my life. I went to a gastroentronologist and was diagnosed with IBS. I always had minor constipation when it wasn't period time and I hadn't been eating good and exercising as usual but this is noticeably worse, and comes with all the goodies of IBS like mucus ew. I'm going to stop taking Yasmin and see if my body starts to work properly again although i'm not looking forward to spending my periods in bed again crying.

A British study suggests that Singulair should be studied for possible psychiatric adverse drugs reactions in children. I don't have this access to this journal so I have to try to find it. I will get back to you on what it says specifically.

BMC Clin Pharmacol. 2008 Mar 17;8(1):1 Links
Individual case safety reports in children in commonly used drug groups - signal detection.Brunlof G, Tukukino C, Wallerstedt SM.
ABSTRACT: BACKGROUND: Due to few paediatric drug safety studies, knowledge on risks of drug treatment in children is limited. The knowledge needs to be increased to make proper risk-benefit analyses possible when treating paediatric patients with drugs. The aim of the present study was to investigate drug groups commonly used in children concerning type and frequency of individual case safety reports in children. METHODS: Number and type of individual case safety reports in the 30 groups of drugs (5th level ATC-code) most sold (number of defined daily doses) in outpatient treatment to children (<5 years old and experiencing psychiatric adverse drug reactions. CONCLUSION: The number of individual case safety reports per million defined daily doses varies in different groups of drugs. A possible signal for montelukast and psychiatric adverse drug reactions was found, which should be further explored.

PMID: 18366638

The key sentence is:

A POSSIBLE SIGNAL FOR MONTELUKAST (SINGULAIR) AND PSYCHIATRIC ADVERSE DRUG REACTIONS WAS FOUND, WHICH SHOULD BE FURTHER EXPLORED.